Designing a retrievable and scalable cell encapsulation device for potential treatment of type 1 diabetes

Published on Jan 9, 2018in Proceedings of the National Academy of Sciences of the United States of America9.412
· DOI :10.1073/PNAS.1708806115
Duo An17
Estimated H-index: 17
(Cornell University),
Alan Chiu17
Estimated H-index: 17
(Cornell University)
+ 16 AuthorsJintu Fan55
Estimated H-index: 55
(Cornell University)
Cell encapsulation has been shown to hold promise for effective, long-term treatment of type 1 diabetes (T1D). However, challenges remain for its clinical applications. For example, there is an unmet need for an encapsulation system that is capable of delivering sufficient cell mass while still allowing convenient retrieval or replacement. Here, we report a simple cell encapsulation design that is readily scalable and conveniently retrievable. The key to this design was to engineer a highly wettable, Ca 2+ -releasing nanoporous polymer thread that promoted uniform in situ cross-linking and strong adhesion of a thin layer of alginate hydrogel around the thread. The device provided immunoprotection of rat islets in immunocompetent C57BL/6 mice in a short-term (1-mo) study, similar to neat alginate fibers. However, the mechanical property of the device, critical for handling and retrieval, was much more robust than the neat alginate fibers due to the reinforcement of the central thread. It also had facile mass transfer due to the short diffusion distance. We demonstrated the therapeutic potential of the device through the correction of chemically induced diabetes in C57BL/6 mice using rat islets for 3 mo as well as in immunodeficient SCID-Beige mice using human islets for 4 mo. We further showed, as a proof of concept, the scalability and retrievability in dogs. After 1 mo of implantation in dogs, the device could be rapidly retrieved through a minimally invasive laparoscopic procedure. This encapsulation device may contribute to a cellular therapy for T1D because of its retrievability and scale-up potential.
Figures & Tables
📖 Papers frequently viewed together
395 Citations
196 Citations
205 Citations
#1Rebecca A. Stokes (USYD: University of Sydney)H-Index: 13
#2Kim Cheng (Garvan Institute of Medical Research)H-Index: 10
Last. Jenny E. GuntonH-Index: 37
view all 10 authors...
Aims/hypothesis Beta cell replacement is a potential cure for type 1 diabetes. In humans, islet transplants are currently infused into the liver via the portal vein, although this site has disadvantages. Here, we investigated alternative transplantation sites for human and murine islets in recipient mice, comparing the portal vein with quadriceps muscle and kidney, liver and spleen capsules.
29 CitationsSource
#1Tejal A. Desai (UCSF: University of California, San Francisco)H-Index: 78
#2Lonnie D. Shea (UM: University of Michigan)H-Index: 81
Islet transplantation can be an effective therapy for patients with type 1 diabetes, but its widespread use is limited by the need for lifelong immunosuppression. Here, Desai and Shea discuss the emerging potential of islet cell encapsulation including new strategies, assess key challenges facing the human translation of this technology and highlight encapsulation devices that have entered the clinic.
196 CitationsSource
26 CitationsSource
#1Shinichi MatsumotoH-Index: 3
#2Masayuki TomiyaH-Index: 1
Last. Osamu SawamotoH-Index: 1
view all 3 authors...
β-Cell replacement therapy, including allogeneic pancreas and islet transplantation, can normalize HbA1c levels in unstable type 1 diabetic (T1D) patients, but a donor shortage is a serious issue. To overcome this problem, xenotransplantation is an attractive option. In fact, islet transplantation from porcine pancreata was performed in the 1990s, which opened the door for islet xenotransplantation, but the possibility of porcine endogenous retrovirus (PERV) infection was raised, which has restr...
23 CitationsSource
#1Jeffrey R. Millman (WashU: Washington University in St. Louis)H-Index: 15
#2Chunhui Xie (Harvard University)H-Index: 2
Last. Douglas A. Melton (Harvard University)H-Index: 125
view all 6 authors...
We recently reported the scalable in vitro production of functional stem cell-derived β-cells (SC-β cells). Here we extend this approach to generate the first SC-β cells from type 1 diabetic patients (T1D). β-cells are destroyed during T1D disease progression, making it difficult to extensively study them in the past. These T1D SC-β cells express β-cell markers, respond to glucose both in vitro and in vivo, prevent alloxan-induced diabetes in mice and respond to anti-diabetic drugs. Furthermore,...
202 CitationsSource
#1Arturo J. Vegas (MIT: Massachusetts Institute of Technology)H-Index: 25
#2Omid Veiseh (MIT: Massachusetts Institute of Technology)H-Index: 42
Last. Daniel G. AndersonH-Index: 119
view all 24 authors...
When encapsulated with alginate derivatives that resist the foreign-body response, human embryonic stem cell–derived beta cells restore long-term normoglycemia in immunocompetent mice without the need for immunosuppression.
395 CitationsSource
Biomaterials: Modified alginates provide a long-term disguise against the foreign body response
3 CitationsSource
#34Robert Langer (MIT: Massachusetts Institute of Technology)H-Index: 296
#35Daniel G. AndersonH-Index: 119
In vivo screening of a large combinatorial library of alginates identifies materials that elicit a substantially reduced foreign body response.
257 CitationsSource
#1Klearchos K. Papas (UA: University of Arizona)H-Index: 32
#2E. S. Avgoustiniatos (UMN: University of Minnesota)H-Index: 18
Last. Thomas M. Suszynski (UMN: University of Minnesota)H-Index: 18
view all 3 authors...
Beta-cell replacement therapy is a promising approach for the treatment of diabetes but is currently limited by the human islet availability and by the need for systemic immunosuppression. Tissue engineering approaches that will enable the utilization of islets or β-cells from alternative sources (such as porcine islets or human stem cell derived beta cells) and minimize or eliminate the need for immunosuppression have the potential to address these critical limitations. However, tissue engineer...
22 Citations
#1Gorka Orive (UPV/EHU: University of the Basque Country)H-Index: 68
#2Edorta Santos (UPV/EHU: University of the Basque Country)H-Index: 12
Last. Dwaine F. EmerichH-Index: 59
view all 8 authors...
Treating many chronic diseases will require a tight, minute-to-minute regulation of therapeutic molecules that is currently not achievable with most pharmaceutical therapies. For these diseases, implantable living cellular systems may be able to provide unlimited drug delivery, enabling seamless matching of treatment duration with disease longevity. Cell encapsulation is an advanced technology that achieves this goal and represents a viable therapeutic option. The advanced state of the field has...
111 CitationsSource
Cited By82
#1Guiling Yu (ECNU: East China Normal University)
#2Mingliang Zhang (SJTU: Shanghai Jiao Tong University)
Last. Haifeng Ye (ECNU: East China Normal University)H-Index: 19
view all 9 authors...
Diabetes affects almost half a billion people, and all individuals with type 1 diabetes (T1D) and a large portion of individuals with type 2 diabetes rely on self-administration of the peptide hormone insulin to achieve glucose control. However, this treatment modality has cumbersome storage and equipment requirements and is susceptible to fatal user error. Here, reasoning that a cell-based therapy could be coupled to an external induction circuit for blood glucose control, as a proof of concept...
#1Siying Wu (SYSU: Sun Yat-sen University)
#2Liying Wang (SYSU: Sun Yat-sen University)H-Index: 5
Last. Jun Wu (SYSU: Sun Yat-sen University)H-Index: 23
view all 6 authors...
Type 1 diabetes mellitus (T1DM) is a chronic metabolic disease caused by the destruction of pancreatic β-cells in response to autoimmune reactions. Shapiro et al. conducted novel islet transplantation with a glucocorticoid-free immunosuppressive agent in 2000 and achieved great success; since then, islet transplantation has been increasingly regarded as a promising strategy for the curative treatment of T1DM. However, many unavoidable challenges, such as a lack of donors, poor revascularization,...
#1Shadab Abadpour (Oslo University Hospital)H-Index: 4
#2Chencheng Wang (Oslo University Hospital)
Last. Hanne Scholz (Oslo University Hospital)H-Index: 19
view all 4 authors...
Beta cell replacement therapy as a form of islet transplantation is a promising alternative therapy with the possibility to make selected patients with type 1 diabetes (T1D) insulin independent. However, this technique faces challenges such as extensive activation of the host immune system post-transplantation, lifelong need for immunosuppression, and the scarcity of islet donor pancreas. Advancement in tissue engineering strategies can improve these challenges and allow for a more widespread ap...
#1Jiang Song (NPU: Northwestern Polytechnical University)H-Index: 1
#2Yanni Zhang (NPU: Northwestern Polytechnical University)
Last. W.X. Huang (NUPT: Nanjing University of Posts and Telecommunications)H-Index: 2
view all 8 authors...
Diabetes is a chronic metabolic disease characterized by high glucose concentration in blood. Conventional management of diabetes requires skin pricking and subcutaneous injection, causing physical pain and physiological issues to diabetic individuals. Hydrogels possess unique advantages such as lightweight, stretchability, biocompatibility, and biodegradability, offering the opportunities to be integrated as flexible devices for diabetes management. This review highlights the development of hyd...
#1Meghan Tahbaz (UCLA Medical Center)
#2Eiji Yoshihara (UCLA Medical Center)H-Index: 1
Insulin injection is currently the main therapy for type 1 diabetes (T1D) or late stage of severe type 2 diabetes (T2D). Human pancreatic islet transplantation confers a significant improvement in glycemic control and prevents life-threatening severe hypoglycemia in T1D patients. However, the shortage of cadaveric human islets limits their therapeutic potential. In addition, chronic immunosuppression, which is required to avoid rejection of transplanted islets, is associated with severe complica...
#1Qingsheng Liu (Cornell University)H-Index: 13
#2Xi Wang (Cornell University)H-Index: 7
Last. Kai Wang (Harvard University)H-Index: 11
view all 12 authors...
Encapsulation of insulin-producing cells is a promising strategy for treatment of type 1 diabetes. However, engineering an encapsulation device that is both safe (i.e., no cell escape and no breakage) and functional (i.e., low foreign-body response (FBR) and high mass transfer) remains a challenge. Here, a family of zwitterionic polyurethanes (ZPU) with sulfobetaine groups in the polymer backbone is developed, which are fabricated into encapsulation devices with tunable nanoporous structures via...
#1Yuhao Zhou (USTC: University of Science and Technology of China)H-Index: 1
#2Chen Zhixiong (CAS: Chinese Academy of Sciences)
Last. Xuesi Chen (USTC: University of Science and Technology of China)H-Index: 115
view all 6 authors...
Oral peptide or protein delivery is considered a revolutionary alternative to daily subcutaneous injection; however, major challenges remain in terms of impediments of the gastrointestinal environment and the intestinal epithelium consisting of mucus and the epithelial cell layer, leading to low bioavailability. To protect against gastrointestinal degradation and promote penetration across the intestinal mucosa, a pH-triggered self-unpacking capsule encapsulating zwitterionic hydrogel-coated met...
2 CitationsSource
#1Bhushan N. Kharbikar (UCSF: University of California, San Francisco)H-Index: 1
#2Gauree S. Chendke (UCSF: University of California, San Francisco)H-Index: 2
Last. Tejal A. Desai (UCSF: University of California, San Francisco)H-Index: 78
view all 3 authors...
Abstract Diabetes Mellitus is a group of diseases characterized by high blood glucose levels due to patients' inability to produce sufficient insulin. Current interventions often require implants that can detect and correct high blood glucose levels with minimal patient intervention. However, these implantable technologies have not reached their full potential in vivo due to the foreign body response and subsequent development of fibrosis. Therefore, for long-term function of implants, modulatin...
5 CitationsSource
#1Andreas Alvin Purnomo Soetedjo (Agency for Science, Technology and Research)
#2Jia Min Lee (NTU: Nanyang Technological University)H-Index: 9
Last. Adrian Kee Keong Teo (Agency for Science, Technology and Research)H-Index: 18
view all 8 authors...
Diabetes is a severe chronic disease worldwide. In various types of diabetes, the pancreatic beta cells fail to secrete sufficient insulin, at some point, to regulate blood glucose levels. Therefore, the replacement of dysfunctional pancreas, islets of Langerhans, or even the insulin-secreting beta cells facilitates physiological regulation of blood glucose levels. However, the current lack of sufficient donor human islets for cell replacement therapy precludes a routine and absolute cure for mo...
1 CitationsSource
#1Xi Wang (Cornell University)H-Index: 7
#2Kristina G. Maxwell (WashU: Washington University in St. Louis)H-Index: 5
Last. Jeffrey R. Millman (WashU: Washington University in St. Louis)H-Index: 15
view all 17 authors...
Transplantation of stem cell-derived β (SC-β) cells represents a promising therapy for type 1 diabetes (T1D). However, the delivery, maintenance, and retrieval of these cells remain a challenge. Here, we report the design of a safe and functional device composed of a highly porous, durable nanofibrous skin and an immunoprotective hydrogel core. The device consists of electrospun medical-grade thermoplastic silicone-polycarbonate-urethane and is soft but tough (~15 megapascal at a rupture strain ...
4 CitationsSource